REFERENCES
- Rothenberg ML, Hainsworth JD, Rosen L, et al. Phase II study of irinotecan (CPT-11) 250 mg/m given every-other-week in previously treated colorectal cancer patients. Proc Ann Soc Clin Oncol 1998; 17: 284a, (abstr. 1092).
- Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 709–715.
- Rougier P, Sugar R, Doullard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluo-rouracil-based chemotherapy. J Clin Oncol 1997; 15: 251–260.
- Pitot HC, Wendr DB, 0 Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15: 2910–2919.
- Rothenberg ML, Echardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 1128–1135.
- Rothenberg ML. Efficacy and toxicity of irinotecan in-patients with colorectal cancer. Semin Oncol 1998; 25 (suppl.11): 39-46.
- Abigerges D, Arnmand JP, Chabot CG, et al. (CPT-11) high dose escalation using intensive high-dose lop-eramide to control diarrhea. J Natl Cancer Inst 1994; 86: 446–449.
- Berg D. Managing the side effects of chemotherapy for colorectal cancer. Semin Oncol 1998; 25 (suppl 11): 53-59.
- Rougier P, Culine S, Bugat R, Suc E, Douillard JY. The European experience with CPT-11 (irinotecan) in the treatment of advanced colorectal cancer. 6th Conference on DNA topoisomerases in therapy, Amsterdam 1995: 6-8/9/(abstr. 74).
- Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivate of camtothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10 (8): 1225–1229.
- Douillard JY, Ibrahim N, Riviere A, et al. Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995; 14, 365 (abstr. 1118).
- Nakagawa K, Fukuoka M, Niitani H. Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced non-small cell lung cancer (NSCL). Proc Am Soc Clin Oncol 1993; 12, (abstr. 1104) .
- Goto K, Nishiwaki Y, Saijo N, et al. A phase II study of irinotecan (CPT-11) and etoposide (VP-16) for metastatic non-small cell lung cancer (NSCLC): Japanese Clinical Oncology Group (JCOG) trial. Proc Am Soc Clin Oncol 1995; 14, 362, (abstr. 1108).
- Boisseau M, Bugat R, Mahjoubi M. Rapid tumor lysis syndrome in a metastatic colorectal cancer increased by treatment with irinotecan (CPT-11). Eur J Cancer 1996; 32A (4): 737–738.
- Milles AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214.
- Sikora K, Advani S, Koroltchouk V, et al. Essential drugs for cancer therapy: A World Health Organization con-sultation. Ann Oncol 1999; 10, 4: 385–390.
- Benson AB III. Therapy for advanced colorectal cancer. Semin Oncol 1998; 25 (suppl. 11): 2-11.
- Van Cutsem E, Cunningham D, Ten Bokkel Huinink W, et al. CPT-11 in 5-FU-resistant colorectal cancer (CRC): Patient benefit. Presented at the European Society for Medical Oncology Congress, November 1-5, 1996, Vienna, Austria.
- Van Hoff DD, Rothenberg ML, Pitot HC, et al. Irinotecan therapy for patients with previously treated metastatic colorectal cancer; Overall results of FDA-reviewed pivotal US clinical trials. Proc Am Soc Clin Oncol 1997; 16: 228, (abstr. 803).
- Toxicological and pharmacological documentation. In: Campto, (irinotecan): Colorectal cancer on the eve of the 21st century. Published by RhOne-Poulenc Rorer, Sept. 1995.